Corina Millo

National Institutes of Health Clinical Center — United States

Medicine · Health Sciences

29h-index3.7kcitations109works4.22yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroendocrine Tumor Research Advances(39), Adrenal and Paraganglionic Tumors(37), Cancer, Hypoxia, and Metabolism(35), Radiopharmaceutical Chemistry and Applications(26), Neuroblastoma Research and Treatments(25)

Publications109 total

Erratum: Phase II Study of 177 Lu-DOTATATE for Progressive Metastatic Pheochromocytomas and Paragangliomas: Interim Analysis of Efficacy, Safety, and Biomarkers

1 cited

Journal of Clinical Oncology·2025· 1 cited

Phase II Study of 177 Lu-DOTATATE for Progressive Metastatic Pheochromocytomas and Paragangliomas: Interim Analysis of Efficacy, Safety, and Biomarkers

3 cited

Journal of Clinical Oncology·2025· 3 citedOpen Access

Effect of absorbed dose on toxicity and tumor response of Lu-177-DOTATATE with olaparib in gastroenteropancreatic neuroendocrine patients: preliminary results

Endocrine Abstracts·2025

Prospective Evaluation of 68Ga-DOTATATE and 18F-DOPA PET Scans in Detecting Tumors Causing Ectopic ACTH Syndrome

1 cited

The Journal of Clinical Endocrinology & Metabolism·2025· 1 cited

Diagnostic performance of [68Ga]DOTATATE PET/CT, [18F]FDG PET/CT, MRI of the spine, and whole-body diagnostic CT and MRI in the detection of spinal bone metastases associated with pheochromocytoma and paraganglioma

16 cited

European Radiology·2024· 16 citedOpen Access

Phase 2 trial of lu-177-DOTATATE in metastatic or inoperable pheochromocytoma/paraganglioma: interim analysis results

4 cited

Endocrine Abstracts·2023· 4 cited

Supplementary Figure 5 from 177Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer

2023Open Access

Data from Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma

2023Open Access

Supplementary Figure 5 from 177Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer

2023Open Access

Supplementary table 2 from 177Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer

2023Open Access

Supplementary Figure 8 from 177Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer

2023Open Access

Supplementary table 3 from 177Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer

2023Open Access

Data from 177Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer

2023Open Access

Supplementary table 3 from 177Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer

2023Open Access

Supplemental Figure 1 from Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma

2023Open Access

Supplementary Figure 7 from 177Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer

2023Open Access

Supplementary table 1 from 177Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer

2023Open Access

Data from Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma

2023Open Access

Supplementary Figure 2 from 177Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer

2023Open Access

Data from 177Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer

2023Open Access

page 1 of 6Next →

Frequent Co-authors

Peter Herscovitch(23), Electron Kebebew(19), Samira M. Sadowski(17), Naris Nilubol(13), Karel Pacák(13), Georgios Z. Papadakis(11), Dhaval Patel(9), Clara C. Chen(8), David Taïeb(8), Ulaş Bağcı(7), Ingo Janssen(6), Karen T. Adams(6), Frank I. Lin(6), Nicholas J. Patronas(6), Robert J. Brychta(5), William J. Dieckmann(5), Alexander Ling(5), Pavel Nockel(5), Jasmine Shell(5), Xavier M. Keutgen(5)